Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133057 | 1.00 | VCP (0.38) | VCPTDP1ATMPTGS2MAPT | |
| SCHEMBL30204572 | 1.00 | VCP (0.38) | VCPTDP1ATMPTGS2MAPT | |
| SCHEMBL6616923 | 0.87 | PTGS2 (0.40) | TDP1ATMPTGS2MAPTALDH1A1 | |
| SCHEMBL6616919 | 0.87 | PTGS2 (0.40) | TDP1ATMPTGS2MAPTALDH1A1 | |
| SCHEMBL394822 | 0.86 | VCAM1 (0.41) | TDP1ATMPTGS2MAPTALDH1A1 | |
| SCHEMBL394821 | 0.86 | VCAM1 (0.41) | TDP1ATMPTGS2MAPTALDH1A1 | |
| SCHEMBL15338608 | 0.84 | VCAM1 (0.36) | VCPTDP1ATMPTGS2MAPT | |
| SCHEMBL25594819 | 0.84 | MAPK1 (0.36) | VCPTDP1ATMPTGS2MAPT | |
| SCHEMBL16727135 | 0.83 | MAPT (0.38) | TDP1ATMPTGS2MAPTALDH1A1 | |
| SCHEMBL17533407 | 0.82 | CYP1A2 (0.42) | TDP1PTGS2MAPTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125683-B1 | 3-BENZOFURANYL-4-INDOLYL-MALEIMIDES AS POTENT GSK-3 INHIBITORS FOR NEURODEGENERATIVE DISORDERS | UNIV ILLINOIS (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8207216-B2 | Benzofuran-3-yl(indol-3-yl) maleimides as potent GSK3 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS | 2010-01-07 | — | — | US | disclosed |
| EP-2125683-A1 | 3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS | The Board of Trustees of the University of Illinois (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1660484-B1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPHA-1 ADRENERGIC AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008077138-A1 | 3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-06-26 | — | — | WO | disclosed |
| CN-100378097-C | Methyl indoles and methyl pyrrolopyridines as alph-1 adrenergic agonists | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | disclosed |
| CN-1784397-A | Methyl indoles and methyl pyrrolopyridines as alph-1 adrenergic agonists | HOFFMANN LA ROCHE (CH) | 2006-06-07 | — | — | CN | disclosed |
| EP-1660484-A1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPHA-1 ADRENERGIC AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| US-6979696-B2 | Method for detecting a gram-negative bacterial autoinducer molecule | ROCHE PALO ALTO LLC (US) | 2005-12-27 | — | — | US | disclosed |
| WO-2004099189-A1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPH-1 ADRENERGIC AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | WO | disclosed |
| US-20040224973-A1 | Substituted indoles as alpha-1 agonists | ROCHE PALO ALTO LLC | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224973-A1 | Substituted indoles as alpha-1 agonists | ADRA1A, ADRB1, ADRA1D | VCP 4647/4885TDP1 1331/4885ATM 3790/4885 |
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | GSK3B, GSK3A, GSKIP | VCP 4483/4885TDP1 1085/4885ATM 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.